参考文献/References:
[1] 王晓卿 ,王雷 ,宋林红 . TFE3融合基因相关肿瘤的临床病理研究进展[J].临床与实验病理学杂志, 2011, 27(11): 1229-1231.
[2] Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer[J]. J Clin Oncol, 2011, 29(25): 3474-3482.
[3] Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry[J]. Clin Cancer Res, 2009, 15(4): 1170-1176.
[4] Chen CJ, Hsu HT, Lin MT, et al. Renal cell carcinoma with t(X; 17)(p11.2;q25) in a 5-year-old Taiwanese boy: a case report and review of the literature[J]. Pathol Oncol Res, 2012, 18(1): 111-116.
[5] Zhong M, De Angelo P, Osborne L, et al. Translocation renal cell carcinomas in adults: a single-institution experience[J]. Am J Surg Pathol, 2012, 36(5): 654-662.
[6] 薛彦诗 ,甘卫东 ,刘铁石 ,等. Xp11.2易位 /TFE3基因融合相关性肾癌的临床与病理分析[J].江苏医药, 2012, 33(5): 537-540.
[7] Dickson BC, Brooks JS, Pasha TL, et al. TFE3 expression in tumors of the microphthalmia-associated transcription factor (MiTF) family[J]. Int J Surg Pathol, 2011, 19(1): 26-30.
[8] Gaillot-Durand L, Chevallier M, Colombel M, et al. Diagnosis of Xp11 translocation renal cell carcinomas in adult patients under 50 years: interest and pitfalls of automated immunohistochemical detection of TFE3 protein[J]. Pathol Res Pract, 2013, 209(2): 83-89.
[9] Martignoni G , Pea M , Gobbo S , et al . Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas [J]. Mod Pathol, 2009, 22(8):1016-1022.
[10] 徐晓晨 ,甘卫东 ,李笑弓 ,等. Xp11.2易位 /TFE3基因融合相关性肾癌与肾透明细胞癌的螺旋 CT诊断鉴别 [J].现代泌尿外科杂志, 2012, 17(2): 122-124.
[11] Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service[J]. Am J Surg Pathol, 2013, 37(8): 1150-1163.
[12] Rao Q, Guan B, Zhou XJ. Xp11.2 translocation renal cell carcinomas have a poorer prognosis than Non -Xp11.2 translocation carcinomas in children and young adults: a meta analysis[J]. Int J Surg Pathol, 2010, 18(6): 458-464.
[13] Meyer PN, Clark JI, Flanigan RC, et al. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults[J]. Am J Clin Pathol, 2007, 128(1): 70-79.
[14] Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma[J]. Cancer, 2010, 116(22): 5219-5225.
[15] Nelius T, Al-Khalil I, Vordermark J, et al. TFE3 translocation-associated renal cell carcinoma presenting as avascular necrosis of the femur in a 19-year-old patient: case report and review of the literature[J]. Case Rep Med, 2011, 2011: 432917.
[16] Bex A, Larkin J, Blank C. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities[J]. Curr Oncol Rep, 2011, 13(3): 240-248.
[17] Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial[J]. Cancer, 2012, 118(23): 5894-5902.
[18] Bambury RM, Battley JE, Mccarthy A, et al. Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated aamily of tumors [J]. Clin Genitourin Cancer, 2013, 11(3): 357-361.
[19] Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread[J].Cancer, 2008, 112(7): 1607-1616.
[20] Argani P, Laé M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood[J]. J Clin Oncol,2006, 24(10): 1529-1534.
[21] Petersson F, Vanecek T, Michal M, et al. A distinctive translocation carcinoma of the kidney; "rosette forming," t (6;11), HMB45-positive renal tumor: a histomorphologic,immunohistochemical, ultrastructural, and molecular genetic study of 4 cases[J]. Hum Pathol, 2012, 43(5): 726-736.
[22] Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t (6;11) (p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum [J]. Am J Surg Pathol,2012, 36(10): 1516-1526.
[23] Argani P, Ladanyi M. Translocation carcinomas of the kidney[J].Clin Lab Med, 2005, 25(2): 363-378.
[24] Kuroda N, Tanaka A, Sasaki N, et al. Review of renal carcinoma with t (6;11)(p21;q12) with focus on clinical and pathobiological aspects[J]. Histol Histopathol, 2013, 28(6): 685-690.
[25] Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation[J]. Am J Surg Pathol, 2012,36(1): 35-42.
[26] Ishihara A, Yamashita Y, Takamori H, et al. Renal carcinoma with (6;11) (p21;q12) translocation: report of an adult case [J].Pathol Int, 2011, 61(9): 539-545.